LOS ANGELES – Sept. 26, 2023 – Stand Up To Cancer® (SU2C) recently awarded seven community organizations with grants to fund efforts to increase diversity in early phase cancer clinical trials. The community engagement grants support SU2C’s focus on addressing disparities in oncology clinical trial participation and facilitating the development of new treatments that have the potential to benefit all patients impacted by cancer. The recipients of these grants operate in four cities – Chicago, Dallas, Los Angeles and Philadelphia – and are deeply connected to communities that are underrepresented in cancer clinical trials.
The community engagement grant recipients will collaborate with four new research teams that are part of the recently announced SU2C Diversity In Early Development Clinical Trials Program, supported by a sponsorship from the Janssen Pharmaceutical Companies of Johnson & Johnson. The research teams are working to create new approaches to engage medically underserved communities in Phase 1 and Phase 2 cancer clinical trials. Community engagement grantees will complement the teams’ work by helping to increase awareness and education within the teams’ focus regions.
“Increasing diverse involvement in cancer therapy development is a critical goal for Stand Up To Cancer and these community collaborators will help us engage with key groups that are experiencing challenges associated with accessing cancer clinical trials,” said Julian Adams, Ph.D., SU2C’s chief science officer. “We strongly feel that by making these important connections between our research teams and organizations embedded in, and trusted by, the key communities we hope to reach, we can amplify our research and begin to meaningfully address cancer disparities.”
Each community engagement grant recipient received a two-year grant. The grantees are:
According to 2020 data from the U.S. Food and Drug Administration, 73% of cancer clinical trial participants are white, 14% are Asian, 6% are Hispanic and 5% are Black. Disparities in clinical trial participation could cause many Americans from diverse groups to be less likely to benefit from new cancer treatments and the promise of precision medicine. SU2C is committed to cancer health equity and is working to increase diversity in SU2C-funded clinical trials, initiate advocacy group collaborations and awareness campaigns, and fund research aimed at improving cancer outcomes and screening rates in medically underserved communities.
# # #
Stand Up To Cancer
Stand Up To Cancer
About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C is a 501(c)(3) charitable organization and was initially launched as a division of the Entertainment Industry Foundation. Established in 2008 by media and entertainment leaders, SU2C utilizes these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of April 2023, more than 3,000 scientists representing more than 210 institutions are involved in SU2C-funded research projects.
As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., conduct rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.
Current members of the SU2C Founders and Advisors Committee (FAC) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Russell Chew serves as SU2C’s president and CEO.